Pershing Square Holdings, the publicly-traded fund run by hedge fund billionaire Bill Ackman, is having a brutal year.
The fund is down 15.9% through October 27, according to a performance update.
The fund’s performance was primarily dragged down by its largest equity holding, Valeant Pharmaceuticals.
Since taking a position earlier this year, Pershing Square has likely lost more than $US1 billion on paper on its investment.
Shares of the Canadian drug company have collapsed since last Wednesday after the California-based short-selling firm Citron Research published a report asking whether Valeant was operating an Enron-like fraud.
Valeant’s share price has declined by more than 34% since the report came out.
Valeant has categorically denied the allegations in the Citron report. The company hosted an all-hands call on Monday morning to address the allegations.
Ackman’s Pershing Square Capital Management owns 21,473,933 shares of Valeant,
including 2 million shares Ackman bought during last Wednesday’s sell-off. Pershing Square is Valeant’s third-largest shareholder.
Ackman first disclosed his position in Valeant on March 17, when the share price was $US200 per share. At that share price, the position was worth $US3.9 billion.
With his added shares from last week, Ackman’s position is worth about $US2.36 billion at Tuesday’s closing share price of $US109.54. That would represent a loss of around $US1.5 billion.
Pershing Square was the best-performing hedge fund last year, returning 40.4%.
Ackman plans to hold a conference call on Friday, the last trading day of the month, to discuss his Valeant investment.
Meanwhile, a number of other positions in his portfolio, including Platform Specialty Products and Canadian Pacific, have declined this year. His short of Herbalife has continued to rise during 2015.
Business Insider Emails & Alerts
Site highlights each day to your inbox.